Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma

  • Sandru A
  • Panaitescu E
  • Voinea S
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Background . Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient’s individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective . To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients. Method . Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4 ng/ml was established using the ROC curve. Results . All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4 ng/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period (P=0.000) . The death risk was 12 times higher in pathological MIA group of patients (P=0.0001) . Conclusions . Our data suggest that MIA is an independent prognostic factor for patients with localized CMM.




Sandru, A., Panaitescu, E., Voinea, S., Bolovan, M., Stanciu, A., Cinca, S., & Blidaru, A. (2014). Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma. Journal of Skin Cancer, 2014, 1–5.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free